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Precision Medicine in Cats: Novel Niemann-Pick Type C1 Diagnosed
by Whole-Genome Sequencing
D.A. Mauler, B. Gandolﬁ, C.R. Reinero, D.P. O’Brien, J.L. Spooner, L.A. Lyons, and 99 Lives Consortium
State-of-the-art health care includes genome sequencing of the patient to identify genetic variants that contribute to either
the cause of their malady or variants that can be targeted to improve treatment. The goal was to introduce state-of-the-art
health care to cats using genomics and a precision medicine approach. To test the feasibility of a precision medicine approach
in domestic cats, a single cat that presented to the University of Missouri, Veterinary Health Center with an undiagnosed
neurologic disease was whole-genome sequenced. The DNA variants from the cat were compared to the DNA variant data-
base produced by the 99 Lives Cat Genome Sequencing Consortium. Approximately 259 genomic coverage was produced
for the cat. A predicted p.H441P missense mutation was identiﬁed in NPC1, the gene causing Niemann-Pick type C1 on cat
chromosome D3.47456793 caused by an adenine-to-cytosine transversion, c.1322A>C. The cat was homozygous for the vari-
ant. The variant was not identiﬁed in any other 73 domestic and 9 wild felids in the sequence database or 190 additionally
genotyped cats of various breeds. The successful eﬀort suggested precision medicine is feasible for cats and other undiagnosed
cats may beneﬁt from a genomic analysis approach. The 99 Lives DNA variant database was suﬃcient but would beneﬁt
from additional cat sequences. Other cats with the mutation may be identiﬁed and could be introduced as a new biomedical
model for NPC1. A genetic test could eliminate the disease variant from the population.
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The genetic and genomic resources available forhealth studies of the domestic cat are becoming
robust and cost eﬃcient. The sequencing of a cat’s
entire genome can now be completed for about the cost
of a magnetic resonance imaging (MRI) scan. In
humans, rapid turnaround whole-genome sequencing
such as the 26-hour genome eﬀorts has demonstrated
how genomic medicine can be applied to health man-
agement for acute care cats with time-critical morbidity
and mortalities.1,2 Although the availability of the
bioinformatics infrastructure and turnaround time are
not yet as accessible in cats as for humans, the DNA
variant database developed by the 99 Lives Cat Gen-
ome Sequencing Initiative has proven a valuable ﬁrst
step. Developed from a variety of cats comprising
diverse populations and breeds, including those with
and without known genetic health problems, the cat
variant database supports the identiﬁcation of DNA
variants that are causal for health conditions suspected
to have a genetic component. Two whole-genome
sequencing (WGS) studies have already identiﬁed a
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ALP alkaline phosphatase
ALT alanine aminotransferase
bp base pair
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oncogene homolog
MRI magnetic resonance imaging
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PCR polymerase chain reaction
qPCR quantitative PCR
WGS whole-genome sequencing
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DNA variant in cats associated with progressive retinal
atrophy in Persians, a variant causing the bobbed tail
of the Japanese Bobtail breed,3 and one responsible for
congenital myasthenic syndrome in Devon rex and
Sphynx—related cats.4
Precision medicine is an emerging approach for dis-
ease diagnosis, treatment, and prevention that takes
into account individual variability in genes, environ-
ment, and lifestyle. Most medical treatments have been
developed for the “average patient”. Precision medicine
gives clinicians tools to better understand the complex
mechanisms underlying a cat’s health, disease, or condi-
tion, and to better predict which treatments will be
most eﬀective, or to determine polymorphisms requiring
diﬀerent drug dosages (pharmacokinetics).5 Overall, an
individual’s speciﬁc genetic makeup will become an
intricate part of their standard health care. This case
report shows the potential to apply precision medicine
to the diagnosis of neurologic disease in cats.
A 12-week-old silver tabby intact female cat of sus-
pected American shorthair lineage presented for a new
kitten examination. Abnormal physical examination
ﬁndings included a pendulous abdomen, soft nonformed
feces, and a shaky, unsteady, hypermetric gait causing
the cat to fall over. A presumptive diagnosis of cerebel-
lar hypoplasia was made. Two months later, she pre-
sented for ovariohysterectomy. During the presurgery
examination, her neurologic signs had progressed and
she was having diﬃculty ambulating. Although well
hydrated, her weight gain was 0.05 kg in 4 weeks. Pre-
surgery blood tests revealed hypoalbuminemia (1.7 g/
dL, reference interval, 2.5–4.4 g/dL), elevated ALT (436
U/L, reference interval 10–118 U/L) and ALP activities
(184 U/L, reference interval 20–150 U/L), hyperbiliru-
binemia (0.6 mg/dL, reference interval 0.1–0.6 mg/dL),
and hyperphosphatemia (7.0 mg/dL, reference interval
2.9–6.6 mg/dL). Abdominal radiographs and ultra-
sonography showed generalized hepatomegaly and sple-
nomegaly. The hepatic parenchyma was hypoechoic and
homogenous. The hepatic vasculature was within nor-
mal limits. The gall bladder was mildly distended with
anechoic bile. Although enlarged, the spleen was
homogenous in echogenicity. The remainder of the
abdominal ultrasound examination was unremarkable.
Postprandial bile acids were elevated (42.1 lmol/L, ref-
erence interval <20 lmol/L). The surgery was canceled
and referral recommended for further evaluation.
The kitten was referred to the University of Missouri,
Veterinary Health Center at 24 weeks of age for evalua-
tion of concurrent hepatic and neurologic disease. On
presentation, she was alert, responsive, well hydrated,
and weighed 2.0 kg. Abnormalities noted included
bradycardia (120 bpm), hepatomegaly, and a distended
bladder. Additional neurologic abnormalities included
inability to walk without support but with good motor
function and hypermetria in all 4 limbs. Palpebral
reﬂexes were normal and the cat was visual, but menace
responses were absent. She also had a horizontal nys-
tagmus with the fast phase to the right.
A serum biochemical proﬁle showed hyperphos-
phatemia (5.6 mg/dL, reference interval, 2–5.3 mg/dL)
consistent with a growing kitten; elevated ALT (326 U/
L, reference interval 18–77 U/L); and ALP (159 U/L,
reference interval 5–55 U/L) activities and total biliru-
bin (0.6 mg/dL, reference interval 0–0.3 mg/dL) most
consistent with hepatocellular injury, cholestasis, and
mild hepatic dysfunction. Serum creatine kinase was
within the reference interval.
Based on the neurologic assessment, the lesion was
localized to the cerebellum. Diﬀerential diagnoses
included infectious disorders, such as toxoplasmosis,
bartonellosis, feline infectious peritonitis encephalitis
and others, a progressive developmental defect, and
storage disorders. Although cerebellar hypoplasia
caused by an intrauterine infection with feline par-
vovirus can produce cerebellar signs, the severity of
signs seen in this cat would make that diagnosis very
unlikely. Normally cats with cerebellar hypoplasia are
ambulatory, and the disease does not progress. A stor-
age disorder was considered the most likely diagnosis
because of the combination of progressive hepatic and
neurologic abnormalities, especially given there was
hepatomegaly. Diagnosis of a storage disease would
require a biopsy, for example, of the liver, which the
owner declined.
When evaluated at 30 weeks of age, the cat was eat-
ing and drinking but had continued to lose weight. She
was nonambulatory, but remained continent if carried
to her litter box. She continued to decline and was euth-
anized at 38 weeks of age. Permission for necropsy was
denied.
Methods
The remaining blood clots from the serum biochemi-
cal proﬁle were processed for DNA isolation6 to aid
diagnosis and to test the concept of precision medicine
for cats, with owner informed consent and in accor-
dance with an approved University of Missouri institu-
tional Animal Care and Use Committee protocol
(ACUC protocol # 8240). The DNA was submitted for
whole-genome sequencing to the McDonnell Genome
Institute at Washington University. The sample was
assessed for quantity, and 1000 ng aliquots were dis-
tributed for library construction. A TruSeq PCR-free
library (Illumina, San Diego, CA) was constructed with
an average fragment size of 350–450 bp. Size selection
was accomplished through a paramagnetic bead cleanup
postfragmentation. The average insert size was expected
to be approximately 350 bp. The concentration of the
library was determined by qPCR according to manufac-
turer’s protocols (Kapa Biosystems, Inc., Woburn, MA)
to optimize cluster counts for the Illumina HiSeq X
(Illumina Inc, San Diego, CA). Library adapters were
designed with 8-bp index sequences allowing for demul-
tiplexing of samples after the sequencing process. Nine
libraries from other cat samples from the 99 Lives pro-
ject (http://felinegenetics.missouri.edu/99lives)3,4 were
pooled together in equal molar ratios, based on the
concentration determined by qPCR and run across a
HiSeq X ﬂow cell to generate ~1 Tb of data as
2 9 150 bp paired-end reads. This eﬃcient pooling
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scheme targets ~309 coverage for each sample. The
Illumina HiSeq X Ten was used to generate sequences.
Approximately 259 genomic coverage was generated
for the case cat. Generated sequences were processed,
and the variants were analyzed with active ﬁlters pro-
vided by Maverix Biomics, Inc. (Santa Cruz, CA) as
previously described3,4 via comparison to the domestic
cat reference genome7 and the genomes of 74 domestic
cats and 9 wild felids of the 99 Lives Cat Genome
Sequencing Initiative. Genes known to be involved with
storage diseases were inspected for the presence of high
and moderate impact variants. DNA variants were ﬁl-
tered by selecting only variants that were homozygous
in the aﬀected cat and not present in any of the other
73 domestic and 9 wild felid sequences in the 99 Lives
sequence database.
Additional screening of the newly identiﬁed NPC1
variant in random bred and breed cats has been per-
formed with an MassArray system (Agena Bioscience,
San Diego, CA) as previously described,3 and primers
details are presented in Table S1.
Results
All data have been or will be submitted to the short-read
archives in the United States and Europe upon publica-
tion. Current submitted sequences are under bioproject
PRJNA308208 (http://www.ncbi.nlm.nih.gov/bioproject/
?term=PRJNA308208). A predicted p.H441P missense
mutation was identiﬁed in NPC1, the gene causing
Niemann-Pick type C1 (NPC1) on cat chromosome
D3.47456793 caused by an adenine-to-cytosine transver-
sion, c.1322A>C. The cat of this report was homozy-
gous for the variant, and no other cats in the dataset
had the variant. The histidine at position 441 is highly
conserved across species (Fig 1). PolyPhen-2 predicts
the amino acid change to be benign with a damaging
score of 0.43 (sensitivity: 0.89; speciﬁcity: 0.90).8 The
NPC1 variant is rare as it was not identiﬁed in 190 cats
(Figure S1).
Discussion
Niemann-Pick type C (NPC) disease (NP-C;
OMIM#257220 and OMIM#607625) is an autosomal
recessive neurovisceral lysosomal storage disorder that
results in defective intracellular transport of choles-
terol. Greater than 95% of all human NPC cases are
because of variants in the NPC1 gene mapped to
chromosome 18q11,9 which is homologous to cat
chromosome D3.7,10 NPC1 in cats was ﬁrst described
as a lipid disorder in a Siamese.11–15 A feline model
of NPC1 (OMIA 000725-9685) is characterized and is
phenotypically, morphologically, and biochemically
similar to human NPC1.16–22 Aﬀected cats show cere-
bellar and vestibular signs beginning as early as
6 weeks of age. The ataxia progresses to the point
where cats fell frequently at 11.8  1.9 weeks of age
and were unable to take 1 step without falling at
17  2.1 weeks age. By 19  3 weeks of age, they
were unable to stand without assistance, and they
were euthanized at 20.5  4.8 weeks of age (range
11–29 weeks).21 The cat in this study was not evalu-
ated before 12 weeks of age but had clear ataxia by
12 weeks of age with diﬃculty walking by 20 weeks
of age. When examined at 24 weeks of age, the cat
could not walk without assistance and she was eutha-
nized at 38 weeks of age. Thus, the onset and pro-
gression of neurologic signs in this cat are
comparable to those observe in the feline NPC1 col-
ony. The cat in this report survived longer before
euthanasia but that likely reﬂects additional nursing
care provided to a pet versus cats in a research col-
ony and reluctance to euthanize on the part of the
owner. Serum ALP and ALT activities were elevated,
and albumin concentrations decreased in the cat in
this report comparable to NPC1 colony cats.22
Histopathology and biochemical studies would be nec-
essary to conﬁrm the diagnosis of NPC1 and demon-
strate an eﬀect of the variant identiﬁed on function.
Unfortunately, the owners declined permission for
biopsy or necropsy. Thus, we cannot prove the diag-
nosis of NPC1, which is a limitation of this study.
Complementation studies using cultured ﬁbroblasts
from NPC-aﬀected cats and NPC1-aﬀected humans
support that the gene responsible for the NPC pheno-
type in this colony of cats is orthologous to the gene
responsible for the major form of human NPC,
NPC1.23 A single base substitution (c.2864G>C) is iden-
tiﬁed in these NPC1-aﬀected cats and in silico predicts
a cysteine to a serine change (p.C955S)24 (GenBank #
AF503633 and AF503634). The known cat NPC1 vari-
ant is predicted to be probably damaging using Poly-
Phen-2 with a score of 0.981 (sensitivity: 0.75;
speciﬁcity: 0.96).8 Heterozygous cats also have meta-
bolic manifestations.19 The parents of the cat could not
be obtained for evaluation. In addition, a published
intronic c.82+5G>A mutation, which leads to a splicing
error in another gene associated with NPC in humans
Fig 1. Protein alignment of NPC1 in cats and other species within critical region for the cat variant H441P. The mutation is within the
luminal topological domain that includes amino acids 372 to 620. The conserved variant site for this case (p.H441P) is presented in bold
italics and underlined. NPC1 in Felis catus has two amino acids shorter compared to human. In humans, three known variants at codon
positions 433, 434, and 451 are associated with a disease phenotype and are bold in the alignment.33–35
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(NPC2), has been identiﬁed in cats with similar
presentation,25 but no signiﬁcant variants were identi-
ﬁed in NPC2 in the cat of this report. However, as pre-
sented in Orphanet (http://www.orpha.net/consor/cgi-
bin/index.php?lng=EN), the mutations in NPC1 occur
in 95% of the families with NPC type disease and more
than 230 mutations have been identiﬁed.
The identiﬁed NPC1 variant in this cat is novel and
predicts a nonconservative missense mutation, a his-
tidine-to-proline substitution at position 441 of the
NCP1 feline protein. The histidine is highly conserved
in several species, and prolines generally cause signiﬁ-
cant disruption to the normal protein structure. The
newly identiﬁed variant is not known in human
patients, but several proline changes and a terminal
variant are within the region of codons 421–474 (http://
www.hgmd.cf.ac.uk/ac).26 Although the PolyPhen-2 pre-
diction was suggested as a benign eﬀect on the protein,
other benign predictions are associated with phenotypic
eﬀects in cats, such as the Gloving variants associated
with KIT that are common to Birmans.7 The NPC1
variant is rare as it was not identiﬁed in 190 cats or the
other 73 domestic cats and 9 wild felids in the 99 Lives
sequence database. However, the population of origin
of the aﬀected cat could not be established for further
screening of a speciﬁc breed.
Precision medicine by WGS has proven to be useful
for diagnosis and rapid intervention and treatment for
critically ill children.1,2 Although the treatments for
NPC1 are not ready for clinical trials in cats and would
not have assisted the present cat, other undiagnosed dis-
eases in cats could beneﬁt from genomics techniques. A
second NPC1 biomedical model in cats could be estab-
lished if other aﬄicted or carrier cats could be identi-
ﬁed, which would further support the development of
potential treatments for the disease. Currently,
cyclodextrin and miglustat have shown improvement in
Purkinje cell survival, thereby preventing cerebellar dys-
function in cats.27–30 Assuming the cat of this report is
representative of a speciﬁc breed, its NPC1 variant
could be segregating in a breeding population and other
homozygous recessive cats may be produced which will
succumb to the same condition if a genetic test is not
implemented to avoid matings between carriers.
To date, over 40 genes with approximately 70 DNA
variants have been documented to cause phenotypic,
disease, or blood type variations in the domestic cat
(for review).31 The clinical descriptions and phenotypes
of each of these diseases and traits have been curated at
the Online Mendelian Inheritance in Animals (OMIA)
website (http://omia.angis.org.au/home/), which is an
invaluable resource comparison of the phenotypes
across 2216 animal species.32 These known and any
newly identiﬁed DNA variants can be genotyped
rapidly and cost-eﬀectively in panels appropriate for
breeds, populations, or in cats as part of wellness care.
The vigilance of veterinarians and their collaboration
with geneticists could lead to the rapid discovery of
undiagnosed genetic conditions in cats, which lead to
more eﬀective and proactive treatments and preventa-
tive strategies. Whole-genome sequencing of rare and
undiagnosed feline cases may be resolved using the pre-
cision medicine approach.
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Supporting Information
Additional Supporting Information may be found
online in the supporting information tab for this article:
Table S1. Genotyping primer sequences for cat NPC1.
Figure S1. Cartesian plot of genotypes detected by
mass spectrometry genotyping. Plot representing the
genotyping results of 96 cats, only the aﬀected Niemann-
Pick type C cat (upward triangle) was homozygous for
the identiﬁed variant (c.1322A>C). One sample (circle)
was excluded for low genotype quality.
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